SG11202003565PA - Aromatic sulfonamide derivatives for the treatment of ischemic stroke - Google Patents
Aromatic sulfonamide derivatives for the treatment of ischemic strokeInfo
- Publication number
- SG11202003565PA SG11202003565PA SG11202003565PA SG11202003565PA SG11202003565PA SG 11202003565P A SG11202003565P A SG 11202003565PA SG 11202003565P A SG11202003565P A SG 11202003565PA SG 11202003565P A SG11202003565P A SG 11202003565PA SG 11202003565P A SG11202003565P A SG 11202003565PA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- ischemic stroke
- sulfonamide derivatives
- aromatic sulfonamide
- aromatic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/26—Radicals substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17199070 | 2017-10-29 | ||
PCT/EP2018/079145 WO2019081573A1 (en) | 2017-10-29 | 2018-10-24 | Aromatic sulfonamide derivatives for the treatment of ischemic stroke |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202003565PA true SG11202003565PA (en) | 2020-05-28 |
Family
ID=60191221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202003565PA SG11202003565PA (en) | 2017-10-29 | 2018-10-24 | Aromatic sulfonamide derivatives for the treatment of ischemic stroke |
Country Status (16)
Country | Link |
---|---|
US (1) | US20210179577A1 (en) |
EP (1) | EP3700891A1 (en) |
JP (1) | JP2021501178A (en) |
KR (1) | KR20200081445A (en) |
CN (1) | CN111511720A (en) |
AU (1) | AU2018356430A1 (en) |
BR (1) | BR112020008484A2 (en) |
CA (1) | CA3079469A1 (en) |
CL (1) | CL2020001139A1 (en) |
EA (1) | EA202091028A1 (en) |
IL (1) | IL274041A (en) |
JO (1) | JOP20200077A1 (en) |
MA (1) | MA50448A (en) |
MX (1) | MX2020004472A (en) |
SG (1) | SG11202003565PA (en) |
WO (1) | WO2019081573A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102388962B1 (en) * | 2016-05-03 | 2022-04-27 | 바이엘 파마 악티엔게젤샤프트 | Aromatic sulfonamide derivatives |
US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
CA3188308A1 (en) | 2020-06-30 | 2022-01-06 | Bayer Aktiengesellschaft | Substituted n-phenylacetamides having p2x4 receptor antagonistic activity |
WO2022049253A1 (en) | 2020-09-07 | 2022-03-10 | Bayer Aktiengesellschaft | Substituted n-heteroaryl-n-pyridinylacetamides as p2x4 modulators |
CN116635020A (en) * | 2021-01-27 | 2023-08-22 | 武汉朗来科技发展有限公司 | Aromatic compound, preparation method and application thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
HRP20211973T1 (en) * | 2009-09-03 | 2022-03-18 | Bristol-Myers Squibb Company | Quinazolines as potassium ion channel inhibitors |
JP2013523658A (en) | 2010-03-26 | 2013-06-17 | グラクソ グループ リミテッド | Pyrazolyl-pyrimidines as kinase inhibitors |
NZ604306A (en) | 2010-05-17 | 2015-02-27 | Incozen Therapeutics Pvt Ltd | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases |
WO2015088565A1 (en) | 2013-12-13 | 2015-06-18 | Sunovion Pharmaceuticals Inc. | P2x4 receptor modulating compounds and methods of use thereof |
WO2015088564A1 (en) | 2013-12-13 | 2015-06-18 | Sunovion Pharmaceuticals Inc. | P2x4 receptor modulating compounds |
CA2988637A1 (en) * | 2015-06-10 | 2016-12-15 | Bayer Pharma Aktiengesellschaft | Aromatic sulfonamide derivatives |
KR102388962B1 (en) * | 2016-05-03 | 2022-04-27 | 바이엘 파마 악티엔게젤샤프트 | Aromatic sulfonamide derivatives |
-
2018
- 2018-10-24 MA MA050448A patent/MA50448A/en unknown
- 2018-10-24 JP JP2020524149A patent/JP2021501178A/en active Pending
- 2018-10-24 US US16/759,970 patent/US20210179577A1/en not_active Abandoned
- 2018-10-24 BR BR112020008484-0A patent/BR112020008484A2/en not_active Application Discontinuation
- 2018-10-24 MX MX2020004472A patent/MX2020004472A/en unknown
- 2018-10-24 CA CA3079469A patent/CA3079469A1/en not_active Abandoned
- 2018-10-24 CN CN201880084317.4A patent/CN111511720A/en active Pending
- 2018-10-24 AU AU2018356430A patent/AU2018356430A1/en not_active Abandoned
- 2018-10-24 JO JOP/2020/0077A patent/JOP20200077A1/en unknown
- 2018-10-24 EA EA202091028A patent/EA202091028A1/en unknown
- 2018-10-24 EP EP18793635.6A patent/EP3700891A1/en not_active Withdrawn
- 2018-10-24 KR KR1020207015477A patent/KR20200081445A/en unknown
- 2018-10-24 WO PCT/EP2018/079145 patent/WO2019081573A1/en active Application Filing
- 2018-10-24 SG SG11202003565PA patent/SG11202003565PA/en unknown
-
2020
- 2020-04-19 IL IL274041A patent/IL274041A/en unknown
- 2020-04-29 CL CL2020001139A patent/CL2020001139A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CL2020001139A1 (en) | 2020-10-23 |
JP2021501178A (en) | 2021-01-14 |
WO2019081573A1 (en) | 2019-05-02 |
CA3079469A1 (en) | 2019-05-02 |
WO2019081573A9 (en) | 2020-05-28 |
MX2020004472A (en) | 2020-08-06 |
EP3700891A1 (en) | 2020-09-02 |
CN111511720A (en) | 2020-08-07 |
KR20200081445A (en) | 2020-07-07 |
IL274041A (en) | 2020-06-30 |
BR112020008484A2 (en) | 2020-10-20 |
US20210179577A1 (en) | 2021-06-17 |
MA50448A (en) | 2020-09-02 |
AU2018356430A1 (en) | 2020-04-30 |
EA202091028A1 (en) | 2020-09-09 |
JOP20200077A1 (en) | 2020-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL272555A (en) | Novel sulfonamide carboxamide compounds | |
IL273786A (en) | Novel sulfonamide carboxamide compounds | |
IL271716A (en) | Novel sulfonamide carboxamide compounds | |
IL272550A (en) | Novel sulfonamide carboxamide compounds | |
ZA201808130B (en) | Aromatic sulfonamide derivatives | |
IL275306A (en) | Devices for ocular surgery | |
BR112016021682A2 (en) | cenicriviroc for the treatment of fibrosis | |
IL274041A (en) | Aromatic sulfonamide derivatives for the treatment of ischemic stroke | |
IL275482A (en) | Esketamine for the treatment of depression | |
EP3525717C0 (en) | Devices for tissue augmentation | |
ZA201900609B (en) | Sulfonamides as gpr40- and gpr120-agonists | |
HK1247558A1 (en) | Cenicriviroc for the treatment of fibrosis | |
PT3412667T (en) | Cocrystal | |
IL274190A (en) | Methods of treating an ischemic disease | |
IL266530A (en) | Treatment for fibrosis | |
GB201800257D0 (en) | New therapeutic uses | |
GB201703750D0 (en) | Ceed 1 | |
GB201712833D0 (en) | Gamblers calcutor |